Zynex, Inc. (NASDAQ:ZYXI) Q2 2023 Earnings Conference Call July 27, 2023 4:15 PM ET
Company Participants
Quinn Callanan - Investor Relations
Thomas Sandgaard - Chairman, President and Chief Executive Officer
Anna Lucsok - Chief Operating Officer
Donald Gregg - Vice President, Zynex Monitoring Solutions
Daniel Moorhead - Chief Financial Officer
Conference Call Participants
Jeffrey Cohen - Ladenburg Thalmann
Operator
Good day ladies and gentlemen, and welcome to the Zynex Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, today's conference call is being recorded.
At this time, I would now like to turn the floor over to Quinn Callanan from MZ North America. Please go ahead.
Quinn Callanan
Thank you, operator and good afternoon everyone. Earlier today, Zynex released financial results for the second quarter ending June 30, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sandgaard, Chairman, President and Chief Executive Officer; Dan Moorhead, Chief Financial Officer; Anna Lucsok, Chief Operating Officer; and Donald Gregg, President of Zynex Monitoring Solutions.
Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation, the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.
With that, I'll now turn this call over to Thomas.
Thomas Sandgaard
Thanks Quinn and good afternoon everyone. Thank you for joining us today for the second quarter 2023 earnings call. The second quarter was highlighted by our continue momentum in both our Pain Management and Pain Monitoring divisions leading us to our 9th consecutive quarter of profitability and fifth straight quarter of record high order numbers. We also once again received the highest number of prescriptions in the company's history beating our previous records. These records led to total revenue for the quarter of $45 million, a 22% increase over the same period in 2022 and we produced $0.09 of earnings per diluted share.